Biogen Inc. BIIB

NASDAQ · Healthcare · Drug Manufacturers - General

$249.59

Close on Fri, 20 Nov 2026 · market value $36.9B

What the price is betting on

Below its record

At $250, the price assumes revenue shrinks about 5% a year for five years, from $10.3B to about $8.3B by FY2030. That is less than what analysts expect for the next two years and less than the company's own last three years.

The price assumes−5%
Analysts, next two years3.5%
Last 3 years1.7%

Revenue growth a year. The price figure comes from a reverse DCF at a 6.2% discount rate.

Track it and Parra checks each report against the path, and tells you when revenue falls behind it.

Own more than BIIB? Check up to 5 of your stocks at once, free, no account.

0$5B$10B$15B$10.3B'22'23'24'25Sep '26'26'27'28'29'30What the price needsReportedAnalysts

Both sides

Three stories, three values

Bear

$366

Base

$413

Bull

$465

Today $250

  • Bear $366. Cash flow grows 1% a year for the next 5 years, slower than expected, then slows to long-run growth.
  • Base $413. Cash flow grows 3% a year for the next 5 years, as analysts expect, then slows to long-run growth.
  • Bull $465. Cash flow grows 5% a year for the next 5 years, faster than expected, then slows to long-run growth.

Stories set by rules from the company’s record.

Checkpoints

The revenue the price needs

  1. YearNeedsAnalysts expect
  2. FY2026$10.2B$10.6B, on the path
  3. FY2027$9.7B$10.8B, on the path
  4. FY2028$9.2B$11.1B, on the path
  5. FY2029$8.7B$11.4B, on the path
  6. FY2030$8.3B$11.6B, on the path

Each year's revenue at −5% growth from $10.3B in the 12 months to September 2026.

At a glance

Healthcare · Drug Manufacturers - General · listed on NASDAQ

Revenue, FY2025
$9.9B
Growth, 3 years a year
1.7%
Cash margin
21%
Net debt
$3.1B
Shares, 3-year change
+0.8%
Dividend yield
0%

What other healthcare prices are betting on

Figures from company filings and end-of-day market data, as of the close on Fri, 20 Nov 2026; updated every trading day. This page shows what today's price assumes, not whether to buy or sell. Not investment advice.